Rohto Pharmaceutical Co.,Ltd.
RPHCF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $42,331,000 | $41,518,000 | $198,540 | $173,567 |
| Dep. & Amort. | $13,143,000 | $8,687,000 | $58,718 | $63,165 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 |
| Change in WC | -$4,181,000 | -$8,877,000 | -$43,777 | $1,167 |
| Other Non-Cash | -$14,376,000 | -$7,083,000 | $30,710,519 | $27,012,102 |
| Operating Cash Flow | $36,917,000 | $34,245,000 | $232,765 | $223,859 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$9,080,000 | -$8,912,000 | -$74,578 | -$93,060 |
| Net Acquisitions | -$74,479,000 | $0 | $820 | -$9,784 |
| Inv. Purchases | -$9,537,000 | -$9,080,000 | -$44,710 | -$46,127 |
| Inv. Sales/Matur. | $5,974,000 | $1,704,000 | $19,879 | $16,126 |
| Other Inv. Act. | -$2,048,000 | -$29,000 | -$13,077,411 | -$16,273,155 |
| Investing Cash Flow | -$89,170,000 | -$16,317,000 | -$13,176,000 | -$16,406,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $31,907,000 | -$1,223,000 | -$9,882,000 | $7,590,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$5,000,000 | $0 | $0 | $0 |
| Dividends Paid | -$7,072,000 | -$5,475,000 | -$4,676,000 | -$3,422,000 |
| Other Fin. Act. | $15,484,000 | -$7,086,000 | -$1,641,000 | -$698,000 |
| Financing Cash Flow | $35,319,000 | -$13,784,000 | -$16,199,000 | $3,470,000 |
| Forex Effect | $3,374,000 | $4,703,000 | $5,236,000 | $4,335,000 |
| Net Chg. in Cash | -$13,341,000 | $8,871,000 | $6,786,000 | $18,651,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $86,562,000 | $77,691,000 | $582,485 | $472,896 |
| End Cash | $73,221,000 | $86,562,000 | $584,780 | $582,485 |
| Free Cash Flow | $26,356,000 | $25,333,000 | $158,187 | $130,799 |